(Total Views: 608)
Posted On: 06/10/2024 10:53:39 PM
Post# of 154624
Quote:
Lilly's results showed a 35% reduction in progress of the disease in 18 months.
Quote:
This delay in progression meant that, on average, participants treated with donanemab had an additional 7.5 months before they reached the same level of cognitive and functional decline on CDR-SB compared to those on placebo.
https://investor.lilly.com/news-releases/news...-presented
I guess 7.5 months is better than nothing unless you get brain bleeding.
(6)
(0)
